Small cap stocks have far outperformed their larger counterparts in November en route to their best monthly performance on record, and look set to remain Wall Street leaders as companies poised to benefit from an economic recovery.
Facebook Inc is close to buying Kustomer in a deal that would value the customer-service and chatbot startup at about US$1 billion, the Wall Street Journal reported on Monday, citing people familiar with the matter. (https://on.wsj.com/3odBJ91)
The Federal Communications Commission (FCC) said Monday it had ended a 2013 regulatory proceeding that had sought to lift the ban on the use of mobile phones while in flight on U.S. airlines.
Bitcoin jumped past US$19,000 on Monday, moving closer to its all-time record after a sharp tumble last week checked its 2020 rally.
Ivory Coast and Ghana are cancelling all cocoa sustainability schemes run by U.S.-based Hershey in the west African countries, accusing the chocolatemaker of trying to avoid paying a cocoa premium aimed at combating farmer poverty.
Food delivery startup DoorDash Inc is aiming to raise up to US$2.8 billion at a valuation of US$27 billion in its initial public offering, setting the stage for one of the most high-profile stock market debuts of the year.
UK airline EasyJet said it would partner with COVID-19 testing companies to offer passengers discounted tests to try to encourage more travel, following similar moves by Wizz Air and London's Gatwick Airport.
The London Stock Exchange's pan-European share trading platform, Turquoise, opened for trading on Monday, a spokeswoman for the exchange said, joining two rival operators.
General Motors Co and Nikola Corp on Monday announced a reworked, smaller agreement that keeps a fuel-cell partnership intact but eliminates an equity stake in the startup for the Detroit automaker as well as plans for building Nikola's electric pickup truck.
Moderna Inc said it will apply for U.S. and European emergency authorization of its COVID-19 vaccine on Monday based on full results from a late-stage study showing its vaccine was 94.1per cent effective with no serious safety concerns.
